COMMENT ON AN ARTICLE: „Coagulopathy in COVID‐19“

We have read with great attention the article "Coagulopathy in COVID-19" written by Toshiaki Iba et al. (Authors), published in the September issue of Journal (1). The Authors performed an effective and informative review. Nevertheless, we welcome the opportunity to make a short comment as well. This very interesting article evaluates current literature regarding harmful hypercoagulable milieu of COVID-19. Surprisingly, we can not see that the Authors recommended other diagnostic considerations such a checking for hyperhomocysteinemia in patients with COVID-19. Undoubtedly, hyperhomocysteinemia has neurotoxic, neuroinflammatory, neurodegenerative, prooxidative, as well as proatherogenic/ prothrombotic effects.